7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis

7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis

Cystic fibrosis (CF) is the most common life-limiting autosomal recessive genetic disorder among individuals of Northern European descent, affecting approximately 1 in 3,000 live births. It is caused by pathogenic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, located on the long arm of chromosome 7 (7q31.2). The CFTR protein functions as an apical cyclic adenosine monophosphate (cAMP)-dependent and protein kinase A (PKA)-activated epithelial anion channel that facilitates the transport of chloride (Cl⁻) and bicarbonate (HCO₃⁻) across epithelial membranes throughout the respiratory, gastrointestinal, hepatobiliary, reproductive, and sweat gland systems. Loss of functional CFTR leads to multi-organ pathology characterized by desiccated secretions, chronic endobronchial infection, progressive bronchiectasis, and exocrine pancreatic insufficiency.

---

Molecular Pathophysiology & CFTR Mutation Classes

The CFTR protein consists of 1,480 amino acids comprising two membrane-spanning domains (MSD1 and MSD2) that form the channel pore, two nucleotide-binding domains (NBD1 and NBD2) that bind and hydrolyze ATP, and a regulatory (R) domain containing multiple phosphorylation sites. Over 2,100 individual mutations in the CFTR gene have been identified. To guide prognosis and molecularly targeted therapeutics, these mutations are categorized into six functional classes based on the primary molecular defect:

CFTR Mutation Classification Architecture:

Nucleus / DNA ───────► Class I: Defective Synthesis (e.g., G542X)
   │
Endoplasmic Reticulum ─► Class II: Processing / Trafficking Block (e.g., F508del)
   │
Golgi / Trafficking ───► Class V: Splicing / Reduced Quantity (e.g., 3849+10kbC->T)
   │
Apical Membrane ──────┬─► Class III: Gating Defect (e.g., G551D)
                      ├─► Class IV: Conduction Defect (e.g., R117H)
                      └─► Class VI: Membrane Instability / Turnover (e.g., 4326delTC)

---

Newborn Screening & Diagnostic Sweat Chloride Testing

Newborn Screening (NBS) Algorithm

Universal newborn screening for CF is standard across all 50 US states. The initial screening test utilizes dried blood spots collected on filter paper (Guthrie card) between 24 and 48 hours of life to quantify immunoreactive trypsinogen (IRT) via radioimmunoassay or enzyme-linked immunosorbent assay (ELISA). In utero pancreatic ductal obstruction causes retrograde leakage of pancreatic zymogens into fetal circulation, resulting in markedly elevated serum IRT levels at birth.

Two primary secondary algorithms are utilized:

1. IRT / DNA: An elevated IRT (e.g., top 4–5th percentile) automatically triggers second-tier genetic analysis using a panel of the 30 to 100+ most prevalent CFTR mutations (including F508del). If one or two mutations are detected, the infant is referred for diagnostic sweat chloride testing.
2. IRT / IRT: If genetic testing is not immediately available, a repeat IRT is obtained at 2 to 3 weeks of life. Persistently elevated IRT mandates sweat testing.

Sweat Chloride Testing: Quantitative Pilocarpine Iontophoresis

The gold standard confirmatory diagnostic test is quantitative sweat chloride determination using pilocarpine iontophoresis (the Gibson-Cooke method or the modern Wescor Macroduct system). Pilocarpine is driven into the skin using a low-voltage electrical current to stimulate local eccrine sweat glands. Sweat is collected over a strict 30-minute interval, and chloride concentration is quantified in millimoles per liter (mmol/L).

To ensure diagnostic accuracy, strict physiological and technical thresholds must be fulfilled:

• Minimum sweat collection weight/volume: ≥75 mg of sweat (Gibson-Cooke) or ≥15 μL (Macroduct system). Sweat collection rates <1 g/m²/min produce artifactually concentrated sweat and invalid results.
• Patient Age: Infants should ideally be at least 48 hours old and clinically stable; testing is most reliable between 2 and 4 weeks of life.

[!IMPORTANT] Diagnostic Criteria for CF: Confirmation of cystic fibrosis requires characteristic clinical features (respiratory, gastrointestinal, or reproductive), a positive newborn screen, or a family history of CF in a sibling, PLUS laboratory evidence of CFTR dysfunction demonstrated by: (1) sweat chloride ≥60 mmol/L on two separate occasions; OR (2) identification of two disease-causing CFTR mutations in trans (one on each parental allele); OR (3) characteristic transepithelial nasal potential difference (NPD) abnormalities.

---

The Pathophysiologic Cascade: Dehydration to Bronchiectasis

In healthy airway epithelia, CFTR actively secretes chloride and bicarbonate into the airway lumen while tonically inhibiting the epithelial sodium channel (ENaC). This coordinated ion transport maintains a hydrated periciliary liquid (PCL) layer approximately 7 micrometers (μm) in depth, allowing cilia to beat synchronously at 10 to 15 Hz to clear inhaled pathogens, cellular debris, and mucus.

In CF airway epithelia, loss of CFTR function produces three catastrophic biophysical shifts:

1. Loss of Apical Chloride and Bicarbonate Efflux: Chloride cannot exit the cell, and bicarbonate secretion is extinguished. The absence of bicarbonate impairs normal mucin unpacking, leading to compact, poorly expanding mucus polymers.
2. Unchecked ENaC Hyperactivity: Loss of tonic CFTR-mediated inhibition results in profound ENaC hyperactivation. Sodium (Na⁺) is hyperabsorbed from the airway lumen into the epithelial cell, drawing water osmotically along its concentration gradient.
3. Airway Surface Liquid (ASL) Dehydration: The PCL layer collapses to <2 μm, physically trapping and flattening the ciliated axonemes against the epithelial surface. Mucociliary clearance ceases completely.

Pathophysiologic Cascade in the CF Airway:

[Absent / Defective CFTR Channel]
              │
              ├──────────────────────────────┐
              ▼                              ▼
   Impaired Cl⁻ & HCO₃⁻ Efflux       Unchecked ENaC Hyperactivation
              │                              │
              └──────────────┬───────────────┘
                             ▼
           Massive Luminal Na⁺ & Water Reabsorption
                             ▼
           Airway Surface Liquid (ASL) Dehydration
                             ▼
       Periciliary Layer Collapse (<2 µm) & Ciliary Failure
                             ▼
           Mucus Stasis, Plugging & Hypoxic Plugs
                             ▼
     Bacterial Colonization (S. aureus, H. flu, P. aeruginosa)
                             ▼
     Massive Neutrophil Influx ──► Extracellular DNA Release (NETs)
                             ▼
     Neutrophil Elastase Release ──► Elastin & Collagen Lysis
                             ▼
       BRONCHIECTASIS, FIBROSIS & END-STAGE LUNG FAILURE

Trapped, desiccated mucus forms intraluminal plugs that create anaerobic microenvironments. Early colonization with Staphylococcus aureus and Haemophilus influenzae triggers a massive, dysregulated host inflammatory response dominated by polymorphonuclear neutrophils (PMNs). Unlike in healthy lungs where neutrophils phagocytose bacteria and undergo apoptosis, CF neutrophils undergo necrotic lysis, releasing massive quantities of high-molecular-weight extracellular DNA (neutrophil extracellular traps [NETs]), actin filaments, and proteolytic enzymes, specifically neutrophil elastase.

This extracellular DNA forms an extensive cross-linked macromolecular matrix that escalates sputum viscosity by orders of magnitude. Simultaneously, uninhibited neutrophil elastase degrades structural elastin and collagen fibers in the bronchial walls, destroys local opsonins and immunoglobulins, and cleaves epithelial tight junctions. The irreversible destruction of muscular and elastic tissue causes dilated, tortuous, thin-walled airways—the hallmark of bronchiectasis.

---

Evidence-Based Airway Clearance Therapy (ACT) Protocol

Daily airway clearance therapy (ACT) is the cornerstone of CF pulmonary preservation. The physical clearance of thick endobronchial secretions cannot occur effectively without prior biochemical hydration and enzymatic liquefaction of mucus. The Cystic Fibrosis Foundation (CFF) establishes a mandatory sequential order of administration for inhaled pulmonary therapies. Administering these medications out of sequence significantly blunts therapeutic efficacy and wastes high-cost therapies.

Mandatory Sequential Order of Daily Respiratory Regimen:

┌─────────────────────────────────────────────────────────────┐
│ STEP 1: Inhaled Bronchodilator                              │
│ (Albuterol 2.5 mg neb or 2-4 puffs MDI with spacer)         │
│ ──► Relaxes bronchial smooth muscle; prevents bronchospasm  │
└──────────────────────────────┬──────────────────────────────┘
                               ▼
┌─────────────────────────────────────────────────────────────┐
│ STEP 2: Inhaled Hypertonic Saline 7%                        │
│ (4 mL nebulized via jet nebulizer)                          │
│ ──► Osmotically rehydrates airway surface liquid (ASL)      │
└──────────────────────────────┬──────────────────────────────┘
                               ▼
┌─────────────────────────────────────────────────────────────┐
│ STEP 3: Inhaled Dornase Alfa (Pulmozyme)                    │
│ (2.5 mg daily via dedicated jet nebulizer)                  │
│ ──► Cleaves extracellular neutrophil DNA; thins sputum      │
└──────────────────────────────┬──────────────────────────────┘
                               ▼
┌─────────────────────────────────────────────────────────────┐
│ STEP 4: Physical Airway Clearance Technique (ACT)           │
│ (High-Frequency Chest Wall Oscillation vest / PEP / CPT)    │
│ ──► Mobilizes and expectorates liquefied secretions         │
└──────────────────────────────┬──────────────────────────────┘
                               ▼
┌─────────────────────────────────────────────────────────────┐
│ STEP 5: Inhaled Antibiotics (ADMINISTERED LAST!)            │
│ (Tobramycin, Aztreonam lysine, or Colistimethate)           │
│ ──► Maximum deposition, penetration & mucosal residence     │
└─────────────────────────────────────────────────────────────┘

Step 1: Inhaled Short-Acting Bronchodilator

• Agent: Albuterol (salbutamol) 2.5 mg via jet nebulizer or 2 to 4 puffs (90 mcg/actuation) via metered-dose inhaler (MDI) with a valved holding chamber, administered 15 to 30 minutes prior to subsequent therapies.
• Mechanism & Rationale: Stimulates β₂-adrenergic receptors on airway smooth muscle, triggering adenylate cyclase-mediated cAMP accumulation and bronchodilation. Pre-treatment opens obstructed lower airways to improve aerosol distribution of downstream agents and crucially prevents bronchospasm provoked by inhaled osmotic irritants (hypertonic saline).

Step 2: Inhaled Hypertonic Saline (7% NaCl)

• Agent: 7% Sodium Chloride Inhalation Solution (4 mL nebulized twice daily via a rapid jet nebulizer; 3% NaCl may be utilized if 7% causes intolerable coughing or bronchospasm despite albuterol pre-treatment).
• Mechanism & Rationale: Creates a steep osmotic gradient across the airway epithelium, drawing water from the submucosa and capillary beds into the airway surface liquid. This rehydrates the collapsed periciliary fluid layer, restores ciliary beat frequency, breaks ionic bonds within the mucin network, and stimulates cough reflex.

Step 3: Recombinant Human Deoxyribonuclease (Dornase Alfa / Pulmozyme)

• Agent: Dornase alfa (Pulmozyme) 2.5 mg (one 2.5 mL ampule) nebulized once daily (some severe patients benefit from 2.5 mg twice daily) using an approved nebulizer system (e.g., Pari LC Plus with a compatible compressor such as Pari Proneb Ultra, or approved vibrating mesh nebulizers).
• Mechanism & Rationale: Dornase alfa is a genetically engineered version of the human extracellular DNase I enzyme. It selectively cleaves phosphodiester bonds in high-molecular-weight extracellular neutrophil DNA without affecting human cellular intracellular genomic DNA. By depolymerizing massive DNA strands into small fragments, it dramatically reduces sputum viscoelasticity, cohesiveness, and adhesiveness within 30 to 60 minutes, converting tenacious gel-like plugs into mobile liquid secretions.
• Compatibility & Storage Mandates:
  • DO NOT MIX: Dornase alfa must never be admixed or co-nebulized with any other medication in the nebulizer cup. Chemical incompatibilities, pH variations, and alterations in osmolarity cause immediate enzyme denaturing, precipitation, and loss of biological activity.
  • Storage: Dornase alfa is a biological protein that is highly thermolabile and light-sensitive. It must be refrigerated at 2°C to 8°C (36°F to 46°F) in its protective foil pouch. Ampules removed from refrigeration must be protected from intense light and heat and discarded if left at room temperature for >24 hours or if the solution appears cloudy or discolored.

Step 4: Airway Clearance Modality (ACT)

• Modality: High-frequency chest wall oscillation (HFCWO / oscillating vest, typically 10–15 Hz for 20–30 minutes), positive expiratory pressure (PEP) mask, oscillating PEP (e.g., Flutter, Acapella, Aerobika), autogenic drainage, or manual chest physiotherapy (percussion and postural drainage).
• Mechanism & Rationale: Once secretions are osmotically hydrated and enzymatically thinned, external oscillatory shearing forces loosen mucus from bronchial walls and propel it from small, peripheral bronchioles into larger central conduits, where it can be expectorated via huff-coughing.

Step 5: Inhaled Antimicrobials (Administered Strictly LAST)

• Agents: Inhaled tobramycin (solution or dry powder), inhaled aztreonam lysine (Cayston), or colistimethate sodium.
• Critical Timing Rationale: Inhaled antibiotics must always be administered LAST, AFTER the completion of airway clearance. If administered prior to clearance, the antibiotic deposits on top of thick, immobile mucus and is immediately coughed out and lost during chest physiotherapy. Administering to clean, cleared airways ensures deep alveolar and bronchiolar aerosol penetration, maximal direct contact with endobronchial Pseudomonas aeruginosa biofilm, and prolonged mucosal residence time without premature mechanical expulsion.

---

Practice Pearls & BCPPS Exam Traps

• Exam Trap 1: Never administer inhaled antibiotics prior to chest physiotherapy or airway clearance. The exam frequently tests a scenario where a nurse or parent gives tobramycin before the vest session to "save time." This is an egregious error; the antibiotic will be coughed into the sputum cup rather than penetrating the airway epithelium.
• Exam Trap 2: Do not co-mix dornase alfa with hypertonic saline, albuterol, or antibiotics in a single nebulizer cup. Dornase alfa is an enzyme; any alteration in pH or ionic strength leads to protein aggregation and irreversible enzymatic denaturation.
• Diagnostic Trap: A sweat chloride of 45 mmol/L in an infant is NOT negative. Values between 30 and 59 mmol/L are intermediate/borderline and require aggressive repeat sweat testing and full CFTR gene sequencing.